President Trump's administration is 'looking at reclassification' of marijuana. What to know about Indiana laws
"We're looking at reclassification and we'll make a determination over the next few weeks," Trump said at news conference August 11.
Though 45 states have legalized the use of marijuana for medicinal or recreational use, the federal government still classifies it as a Schedule I drug.
Here's what a Schedule I drug is and what to know about marijuana laws in Indiana as well as around the country.
Schedule I drugs are defined as highly dangerous, addictive and without medical use. Marijuana has belonged to this class of drugs since the Controlled Substances Act was signed in 1970. If reclassified, marijuana would be treated the same as drugs like Tylenol with codeine and anabolic steroids, which can be prescribed by licensed health care providers and dispensed by licensed pharmacies.
Reclassifying marijuana would be the biggest change in marijuana policy the federal government has taken since the drug was first outlawed, but it would not make recreational usage legal under federal law.
No. In Indiana, weed is not legal for recreational or medical use.
CBD, Delta-9 THC and THCA, which are alternatives to marijuana, are available for legal purchase at vape shops in Indiana as long as those levels don't exceed the legal limit. Any THC product with a higher level than 0.3% is classified as marijuana and therefore still illegal.
Cannabis cheat code: Marijuana is illegal in Indiana, but this loophole makes it complicated
Marijuana is legal for both recreational and medicinal use in 24 states and the District of Columbia as of April 2025, according to DISA Global Solutions. The states are listed below:
46 states, Washington DC and three U.S. territories have approved some form of cannabis for medicinal use. Nebraska is the most recent state to vote in favor of medical marijuana.
Story continues after photo gallery.
Marijuana was banned federally in 1970 with the passage of the Controlled Substances Act, which classified marijuana as a Schedule I drug.
More on cannabis: What's the difference between Delta 8 THC and marijuana or 'weed'?
Marijuana is fully illegal for both medicinal and recreational use and has not been decriminalized in four additional states:
There are also a few states where medical and recreational marijuana isn't legalized, but is decriminalized.
Kayla Dwyer and Greta Cross contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
2 hours ago
- Boston Globe
Whoop there it is: FDA wants to regulate wearable firm's blood pressure tool
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up But in a response sent Aug. 4, Whoop rejected the FDA's assessment, saying the software didn't meet the definition of a medical device and the company would continue to offer the feature to users. The company, which shared the letter with The Boston Globe, also argued the move went against the goals of the Trump administration. Advertisement 'Seeking to regulate the feature as a medical device also runs counter to the stated policy of the Secretary of the Department of Health and Human Services, Robert F. Kennedy Jr., of 'clearing away regulatory barriers so innovation can thrive,'' Whoop said in the letter. Advertisement Whoop's refusal to comply with the FDA's request is uncommon, legal experts said. The FDA, which oversees the safety of medical devices and pharmaceuticals, is usually the ultimate decider of what comes under its jurisdiction and which devices can be sold to help people manage or treat health conditions. Chris Robertson, a Boston University law professor who teaches FDA law, said any communication from the FDA to a company is typically enough to make the company get in line with federal standards. 'You're playing with fire here,' Robertson said. 'That means that Whoop is taking a real calculated gamble.' Wearable technology sits in a grey area when it comes to regulation. The wearables market, estimated by one market intelligence group to be worth $84 billion in 2024, is rapidly expanding, and companies are racing to add new features that give users unique health measurements. Related : Smart wristbands, watches and rings that assess heart rates don't have to get cleared as medical devices. But Whoop competitors, such as Apple and Fitbit, have sought FDA approval for certain software tools in recent years. The crux of Whoop's argument rests on the 21st Century Cures Act, a 2016 law that exempts wellness software features from the definition of a medical device, so long as those features aren't related to the diagnosis, prevention, or treatment of a disease. Blood Pressure Insights, Whoop said, is only intended to be used as a way to gauge a person's performance, quality of sleep, and stress levels . The FDA, however, has rejected Whoop's characterization of the blood pressure tool. In its letter, the agency said the product qualifies as a medical device because its measurements are 'inherently associated with the diagnosis of a disease or condition,' such as hypertension, or high blood pressure. Advertisement Whoop has registered one of its products with the FDA, securing medical device approval for its Heart Screener tool. That tool measures the heart's electrical activity to alert users to potentially abnormal heart rates and atrial fibrillation, a common type of abnormal heart rhythm. The FDA said it doesn't comment on 'ongoing investigations, compliance matters or enforcement activities except with the company involved.' Related : The confrontation is reminiscent of the clash more than a decade ago between the FDA and the personal genomics platform 23andMe, said health law expert Frances Miller, who also teaches at Boston University. The FDA and 23andMe went back and forth on whether the company's health test — which the company claimed could tell customers their risk of conditions like gallstones, heart disease, or arthritis — constituted a medical device. In 2013, the FDA sent a warning letter to 23andMe much like the one it sent Whoop, and 23andMe ultimately capitulated. But the landscape looks different today, Miller said. The FDA has experienced significant cuts under President Trump, and federal agencies as a whole have lost power. In addition, Kennedy has publicly stated his vision that 'every American is wearing a wearable within four years.' Whether Whoop will win its fight against regulation is unclear, Miller said. 'I could have given you a very confident answer a year and a half ago,' Miller said. 'Not now. They're pushing the envelope.' Marin Wolf can be reached at
Boston Globe
2 hours ago
- Boston Globe
At UMass Memorial Health, a worrisome diagnosis on the future of health care
With more than half of the hospitals in Massachusetts currently in the red, Alan Sager, a Boston University professor of health law, policy, and management, said the Medicaid cuts will only compound the difficult financial decisions many are already facing. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'There will be program closures,' Sager said. 'There will be individual patients who don't get care because they lost coverage or because the program that served them was eliminated.' Advertisement The dominant provider of medical care in Central Massachusetts, UMass Memorial treats some 500,000 patients a year, more than a quarter of them covered by Medicaid, the government health insurance for the poor and disabled. About one in 20 UMass Memorial patients are uninsured, which means the health system often has to absorb the costs of treatment, adding to the financial strain. Dr. Eric Dickson, the UMass Memorial chief executive, said the recent program closures were made in part to offset recent financial shortfalls, but also were driven by the impending cuts to Medicaid. Advertisement President Trump's signature legislation, the One Big Beautiful Bill Act, will slash nearly $1 trillion from Medicaid over the next 10 years, tossing up to 16 million Americans from health insurance program, according to the nonpartisan Congressional Budget Office. UMass Memorial estimates that 100,000 of its patients are at risk of losing Medicaid coverage because of new eligibility and work requirements. President Trump signed his signature bill of tax breaks and spending cuts at the White House on July 4. Evan Vucci/Associated Press Prior to enactment of the law, Dickson said he believed he could manage the operating losses and return to profitability 'in a slow, thoughtful manner.' But the massive cuts to Medicaid mean UMass Memorial could no longer take a gradual approach. 'I went back to my board' of directors, Dickson recalled, 'and said. 'I've got to move hard and fast.'' The financial outlook has undoubtedly become darker for hospital systems such as UMass Memorial that care for high numbers of low-income and uninsured patients, said Karen Errichetti, an assistant professor of public health and community medicine at Tufts School of Medicine. But Medicaid cuts are only one source of the instability. Costs of labor, drugs, and medical supplies are up, while hospitals serving large low-income populations tend to operate on razor-thin margins. Total expenses for hospitals in 2024 grew by 5.1 percent, well above outpacing the overall rate of inflation of 2.9 percent , according to the American Hospital Association's Advertisement 'UMass is a very important safety net hospital system within our state and has an important role to play in that larger community that needs a safety net,' said Errichetti. 'The things going on right now are a sign of broad pressures on safety net hospitals in general.' Across the state, health systems have shuttered clinics offering mental health services, obstetrics, and primary care as they attempted to balance their budgets. Between 2014 and 2023, Protesters rallied against the planned closure of the labor and delivery unit at the UMass Memorial HealthAlliance-Clinton Hospital in Leominster on May 30, 2023. Nathan Klima for The Boston Globe Dickson said UMass Memorial as a whole is 'too big to fail,' because it treats so many people in Central Massachusetts. But non-emergency services, such as primary care or mental health programs, could be at risk if its finances worsen. Most recently, UMass Memorial said it will shut down a psychiatric day program for adults in Fitchburg as of Oct. 23. The program, call BUDD, for Builds Understanding and Develops Direction, serves about 30 patients, treating them for psychosocial, emotional, or behavioral issues and connecting them with social workers, psychiatrists, and rehabilitation counselors. The BUDD program is operated by UMass Memorial affiliate Community Healthlink, which provides a range of services addressing mental health, substance abuse, and homelessness. CHL has served more than 14,000 people since since January 2024. It also lost $10.4 million between October and March. If losses continue to grow, Dickson said, he might be forced to shutter Community Healthlink outright. It is among the most comprehensive providers of community-based mental health and substance use treatment in Worcester County, and its closure would ripple across the health care system. Advertisement 'What happens when you stop seeing behavioral health patients at CHL, you stop doing detox, you stop housing people with substance use disorder or working with families in crisis? Where do they end up going for care? The emergency department,' Dickson said. 'And my emergency departments are completely overwhelmed right now.' Marin Wolf can be reached at
Yahoo
3 hours ago
- Yahoo
Trump's chief intervened to save RFK Jr.'s top vaccine aide
White House Chief of Staff Susie Wiles was behind President Donald Trump's highly unusual decision last week to rehire a vaccine regulator he'd just fired at the urging of MAGA influencer Laura Loomer. Wiles' intervention in getting Vinay Prasad's job back, as described by two senior administration officials granted anonymity to discuss sensitive details, followed pleas from both Prasad's boss, Food and Drug Administration Commissioner Marty Makary, and Health Secretary Robert F. Kennedy Jr. They insisted that Prasad is part of Kennedy's broader 'make America healthy again' movement and integral to the Trump coalition. 'After Vinay left, Marty and Bobby worked very, very, very hard through Susie Wiles, the president's chief of staff, to tell the president that Vinay was not anti-Trump,' one of the senior administration officials said. 'The MAHA movement is an expansion of the MAGA, sort of, you know, big tent.' Trump's reversal demonstrated the limits of Loomer's influence and marked a fragile win for Kennedy in pursuing his plans to overhaul U.S. regulation of vaccines and drugs — and confirmation that the White House still sees Kennedy as a useful political ally as the midterm elections approach. Trump had forced Prasad out of his FDA job less than two weeks earlier after the Cambridge, Massachusetts, pharmaceutical manufacturer Sarepta Therapeutics, joined by GOP allies and Loomer, sought his ouster. Prasad in July had pushed the FDA to ask Sarepta to stop selling its Duchenne muscular dystrophy drug Elevidys due to safety concerns, according to one of the senior administration officials. Sarepta spokesperson Tracy Sorrentino wrote in an email that the company will 'continue working with the FDA, its leadership and review teams, as we have always done." In arguing Prasad was disloyal to Trump, Loomer had pointed to social media posts he made during the pandemic, in which Prasad said that he was once a Bernie Sanders supporter. Prasad's rehiring isn't the end of the war between Kennedy and his allies, and Loomer and corporations – from pharma to food manufacturers – that see Kennedy as a threat. Loomer, for instance, has only amped up her critique, most recently telling POLITICO that she planned to go after more Kennedy aides. Loomer remains close to Trump and he has occasionally, though not always, followed her advice on personnel decisions. Loomer did not respond immediately to a request for comment. The FDA referred questions to the White House. 'Secretary Kennedy and the entire HHS team are doing a terrific job as they deliver on President Trump's mandate to Make America Healthy Again," White House spokesperson Kush Desai said. "Scores of prominent restaurant chains and food brands dropping artificial ingredients from our food supply and historic reforms at the FDA to fast track lifesaving drugs and treatments prove that the entire HHS team is delivering for the American people.' According to the officials, Makary and Kennedy persuaded the White House to review statements by Prasad that Loomer said showed disloyalty, arguing they were taken out of context. 'I think it really is something good about the president that he's willing to change his mind when persuaded,' one of the senior administration officials said. But the victory could prove pyrrhic if Prasad's ability to set policy is diminished. Before his firing, Makary had named him not only the head of the FDA's Center for Biologics Evaluation and Research, which oversees regulation of vaccines and gene therapies like Elevidys, but also the agency's chief medical and scientific officer. Makary, like Prasad, was a leading critic of the Biden administration's response to the Covid pandemic. Prasad, a University of Chicago-trained hematologist and oncologist, was previously a professor of epidemiology and biostatistics at the University of California, San Francisco. Sen. Ron Johnson (R-Wis.), the author of a 2018 law Trump signed that permits patients greater access to experimental therapies, told POLITICO he texted Trump days ahead of Prasad's ouster to raise concerns of the Duchenne muscular dystrophy patient community about the FDA's efforts to restrict Elevidys. The company initially refused to comply with the agency's July 18 request that it halt shipment. It agreed on July 21 to stop shipping the medicine by the end of business the next day to maintain a 'productive and positive working relationship with FDA.' The agency then allowed the company to resume distribution to ambulatory patients on July 28, a day before Prasad's ouster. Those patients are a subset of people with the condition, which weakens muscles and leads to the loss of the ability to walk, typically by age 12. Most die before they reach 30. Johnson's Right to Try Act, which Trump repeatedly touted on the campaign trail as a signature achievement of his first term, aims to allow patients with life-threatening diseases to try experimental medicines without FDA involvement. The agency has a separate longstanding program known as compassionate use that allows such patients to access experimental treatments when other options do not exist. 'I have never met or spoken to Dr. Prasad,' Johnson said when asked about Prasad's return. 'I hope all the new appointees within HHS and its subsidiary agencies restore integrity to scientific research, fully respect both the letter and spirit of the Right to Try Act, and carefully listen to and empathize with the patients who are impacted by their decisions.' Former FDA officials said they expect the power struggle between Republicans who support pharma and Kennedy to continue. Loomer, meanwhile, says she now wants Trump to dismiss Stefanie Spear, Kennedy's principal deputy chief of staff and senior counselor, and Casey Means, Trump's nominee to be surgeon general. Casey Means is a close Kennedy ally and sister of Kennedy adviser Calley Means. 'I think she wants to split the MAHA and MAGA coalition,' one of the senior officials said of Loomer. 'She wants to split them in two.' Tim Röhn is a member of the Axel Springer Global Network.
